Heterocyclic Building Blocks-isoxazole

Some dimethyldiisoxazolone derivatives was written by Caramella, Pierluigi;Gruenanger, Paolo. And the article was included in Chimica e l’Industria (Milan, Italy) in 1967.Related Products of 19668-85-0 This article mentions the following:

3-Methyl-4-(3-methylisoxazol-5-yl)-3-isoxazolin-5-one [I (R = H)] (II) is prepared and used in the preparation of III and IV. II, m. 169-70° (decomposition), is prepared according to 3 known methods. A solution is prepared from 9.0 g. II and 38 ml. POCl3, 7.0 ml. Et3N is slowly added, and the mixture is refluxed 90 min. to give 64% III (X = Cl) (V), m. 89-90° (hexane). A mixture of 1.0 g. V in C6H6 is treated with 3.0 ml. morpholine and the mixture is kept 2 days to give 96% III (X = morpholino), m. 89-90° (cyclohexane); N.M.R. data are given. A solution of 1.0 g. V in 30 ml. 0.24M KOH (MeOH) is agitated 3 hrs. to give 72% III (X = MeO) (VI), m. 73-4° (ligroine). Similarly prepared is III (X = EtO), m. 89-90° (hexane). VI (0.5 g.) in 50 ml. MeOH is hydrogenated in the presence of 0.1 g. 5% Pd/C to give 90% Me 2-(3-methylisoxazol-5-yl)-3-aminocrotonate (VII), m. 91-2° (C6H6-hexane). Similarly prepared is IV [R = C(CO2Et):C(NH2)Me] (VIII), m. 106-7° (C6H6-hexane); acetyl derivative m. 84-5° (cyclohexane). A mixture of 2.55 millimoles VII (or VIII) and 15 ml. 1:1 H2SO4 is refluxed 1 hr. to give IV (R = CH2CO2H), m. 106-7° (C6H6). A solution of 120 mg. VII and 50 mg. HONH2.HCl in 20 ml. EtOH is refluxed 2 hrs. to give 82% II, m. 167-8° (decomposition) (water). A solution of 0.5 g. VII and 0.22 g. HONHMe.HCl in 20 ml. EtOH is refluxed 2 hrs. to give 71% I (R = Me) (VIII), m. 163-4° (water). II (10 millimoles) is treated with excess CH2N2 to give a mixture of VI and VIII. Similarly prepared is a mixture of III (X = EtO) (IX) and I (R = Et) (X), m. 97-8° (iso-Pr2O). A mixture of 4.5 millimoles II in 10 ml. water is neutralized with 0.5N NaOH, 0.1N AgNO3 is added, and the mixture is heated with MeI in C6H6 to give a mixture of VI and VIII. Similarly prepared is a mixture of IX and X. Ir and uv data are given. In the experiment, the researchers used many compounds, for example, 3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0Related Products of 19668-85-0).

3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Related Products of 19668-85-0

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Regio- and stereoselective synthesis of 2-alkylidene-hydrofurans by domino-cyclodialkylations of 1,3-dicarbonyl-dianions with 1-bromo-2-chloroethane was written by Langer, Peter;Karime, Inass. And the article was included in Synlett in 2000.SDS of cas: 5765-44-6 This article mentions the following:

Reaction of 1,3-dicarbonyl dianions with 1-bromo-2-chloroethane results in regio- and stereoselective formation of 2-alkylidene-hydrofurans, e.g. I. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6SDS of cas: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.SDS of cas: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The coordination chemistry of (py)₂BF⁺₂ and related difluoroboron cations was written by Stephen Hartman, J.;Shoemaker, James A. W.;Janzen, Alex F.;Ragogna, Paul J.;Szerminski, W. R.. And the article was included in Journal of Fluorine Chemistry in 2003.Quality Control of 5-Methylisoxazole This article mentions the following:

The substitution and decomposition reactions of the difluorobis(pyridine)boron(III) cation, and of several substituted pyridine and other difluoroboron cations (D)₂BF₂⁺, are explored. Donor mol. displacement is greatly accelerated by the presence of electron-withdrawing meta and para pyridine substituents in (substituted pyridine)₂BF₂⁺ cations, and by electron-donating substituents on pyridine when the substituted pyridine is the attacking species. Increased steric hindrance of D in D₂BF₂⁺, and of the attacking base D’, slows or prevents displacement of D by D’. [(Py)₂BF₂][PF₆] (py = pyridine) undergoes slow decomposition in acetone, giving initially py·BF₃ and finally [py·H][BF₄] as the major fluoroboron species. A 2nd decomposition pathway, giving rise to BF₃OH^– and several addnl. F-containing products, is favored by the presence of strong bases such as amidines and by the presence of N-H and O-H bonds. Increased susceptibility to ligand displacement facilitates the synthesis of new fluoroboron cations, but also increases the susceptibility to decomposition In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Quality Control of 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Quality Control of 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials was written by Gul, Seref;Ozcan, Onur;Asar, Sinan;Okyar, Alper;Baris, Ibrahim;Kavakli, Ibrahim Halil. And the article was included in Journal of Biomolecular Structure and Dynamics in 2021.Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clin. proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clin. approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL^pro) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for mol. dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiol. conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL^pro based on MD simulation results. Similar anal. with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clin. trials for the treatment of SARS-CoV-2-infected patients. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach was written by Chen, Fang;Liu, Hongrui;Wang, Bing;Yang, Zhou;Chen, Yusheng;Yang, Liuliu;Jiao, Zheng;Lin, Hai-Shu;Quan, Yingjun;Wang, Hao;Xiang, Xiaoqiang. And the article was included in AAPS PharmSciTech in 2020.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

The purpose of this study was to investigate the impacts of the formulation parameters on the pharmacokinetics and bioequivalence of risperidone orodispersible film (ODF) using physiol. based pharmacokinetic model. The pharmacokinetic profiles of two risperidone ODFs, which exhibit different in vitro dissolution, were examined in Beagle dogs after supralingual administration. Subsequently, a physiol. based pharmacokinetic (PBPK) model was constructed to evaluate the in vivo performance of risperidone ODF. The parameter sensitivity anal. (PSA) was used to access the impacts of formulation parameters on the pharmacokinetics of risperidone. Moreover, the validated PBPK model was applied to predict human pharmacokinetic profiles and examine the bioequivalence of these two ODFs. These two ODFs displayed similar risperidone pharmacokinetic profiles in dogs. The parameter sensitivity anal. indicated that the changes in the solubility, particle size, particle d., and diffusion coefficient did not have obvious influence on the in vivo properties of risperidone ODF. Alternation of the in vitro complete dissolution time in water from 15 to 30 min led to a 30% decrease in Cmax and 20% of increase in Tmax. AUC0-∞ would be decreased if risperidone was not fully released within 1 h. As both ODFs completely released risperidone within 15 min, the difference in the extent of in vivo absorption, intestinal regional absorption location, and plasma concentration-time curves between these two ODFs was almost negligible. Consequently, a bioequivalence was foreseen in humans. The in vitro cumulative dissolution percentage in water at 15 min was found to be the major determinant on the in vivo properties of risperidone ODF. PBPK modeling appears to be an innovative strategy to guide the development of risperidone ODF. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases was written by Brown, Dearg S.;Cumming, John G.;Bethel, Paul;Finlayson, Jonathan;Gerhardt, Stefan;Nash, Ian;Pauptit, Richard A.;Pike, Kurt G.;Reid, Alan;Snelson, Wendy;Swallow, Steve;Thompson, Caroline. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2012.Related Products of 14678-05-8 This article mentions the following:

A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clin. candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703). Optimization was guided by understanding of the binding modes from X-ray crystallog. studies which showed a switch from DFG out’ to DFG in’ as the inhibitor size was reduced to improve overall properties. In the experiment, the researchers used many compounds, for example, Isoxazol-5-amine (cas: 14678-05-8Related Products of 14678-05-8).

Isoxazol-5-amine (cas: 14678-05-8) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Related Products of 14678-05-8

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

External evaluation of risperidone population pharmacokinetic models using opportunistic pediatric data was written by Karatza, Eleni;Ganguly, Samit;Hornik, Chi D.;Muller, William J.;Al-Uzri, Amira;James, Laura;Balevic, Stephen J.;Gonzalez, Daniel. And the article was included in Frontiers in Pharmacology in 2022.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Risperidone is approved to treat schizophrenia in adolescents and autistic disorder and bipolar mania in children and adolescents. It is also used off-label in younger children for various psychiatric disorders. Several population pharmacokinetic models of risperidone and 9-OH-risperidone have been published. The objectives of this study were to assess whether opportunistically collected pediatric data can be used to evaluate risperidone population pharmacokinetic models externally and to identify a robust model for precision dosing in children. A total of 103 concentrations of risperidone and 112 concentrations of 9-OH-risperidone, collected from 62 pediatric patients (0.16-16.8 years of age), were used in the present study. The predictive performance of five published population pharmacokinetic models (four joint parent-metabolite models and one parent only) was assessed for accuracy and precision of the predictions using statistical criteria, goodness of fit plots, prediction-corrected visual predictive checks (pcVPCs), and normalized prediction distribution errors (NPDEs). The tested models produced similarly precise predictions (Root Mean Square Error [RMSE]) ranging from 0.021 to 0.027 nmol/mL for risperidone and 0.053-0.065 nmol/mL for 9-OH-risperidone). However, one of the models (a one-compartment mixture model with clearance estimated for three subpopulations) developed with a rich dataset presented fewer biases (Mean Percent Error [MPE, %] of 1.0% vs. 101.4, 146.9, 260.4, and 292.4%) for risperidone. In contrast, a model developed with fewer data and a more similar population to the one used for the external evaluation presented fewer biases for 9-OH-risperidone (MPE: 17% vs. 69.9, 47.8, and 82.9%). None of the models evaluated seemed to be generalizable to the population used in this anal. All the models had a modest predictive performance, potentially suggesting that sources of inter-individual variability were not entirely captured and that opportunistic data from a highly heterogeneous population are likely not the most appropriate data to evaluate risperidone models externally. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T was written by Godlewska, Beata R.;Minichino, Amedeo;Emir, Uzay;Angelescu, Ilinca;Lennox, Belinda;Micunovic, Masa;Howes, Oliver;Cowen, Philip J.. And the article was included in Translational Psychiatry in 2021.Recommanded Product: 144598-75-4 This article mentions the following:

Abnormalities in glutamate neurotransmission are linked to psychotic symptoms and cognitive dysfunction in schizophrenia. magnetic resonance spectroscopy (MRS) provides an acceptable means of measuring glutamate in the human brain but findings from patient studies at conventional magnetic field strength show considerable heterogeneity. Ultra-high-field MRS offers greater precision in glutamate measurement, particularly in delineation of glutamate from its precursor and metabolite, glutamine. This study aimed to use high-field (7 T) MRS to measure concentrations of glutamate and glutamine in three brain regions, anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC) and putamen (PUT), in young men with early psychosis. MRS was performed in 17 male participants with early psychosis and 18 healthy age-matched controls. Neurometabolite levels were calculated with unsuppressed water signal as the reference and corrected for individual gray matter, white matter and cerebrospinal fluid concentration Cognitive function was measured with the Brief Assessment of Cognition in Schizophrenia (BACS). Compared to controls, patients with early psychosis had lower concentrations of glutamate and glutamine in ACC. No differences were apparent in the DLPFC and PUT. In patients with early psychosis, there was a highly significant correlation between glutamate concentration in ACC and performance on the BACS, though the numbers available for this anal. were small. Our finding of lower glutamate levels in ACC in patients with schizophrenia is consistent with a recent meta-anal. of 7 T studies and suggests that this abnormality is present in both patients with early psychosis and those with longer-established illness. The possible link between ACC glutamate and cognitive performance requires replication in larger studies. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Recommanded Product: 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. Isoxazoles are commonly used as enaminoketone or β-diketone surrogate. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Recommanded Product: 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Known drugs identified by structure-based virtual screening are able to bind sigma-1 receptor and increase growth of huntington disease patient-derived cells was written by Battista, Theo;Pascarella, Gianmarco;Staid, David Sasah;Colotti, Gianni;Rosati, Jessica;Fiorillo, Annarita;Casamassa, Alessia. And the article was included in International Journal of Molecular Sciences in 2021.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Huntington disease (HD) is a devastating and presently untreatable neurodegenerative disease characterized by progressively disabling motor and mental manifestations. The sigma-1 receptor (σ1R) is a protein expressed in the central nervous system, whose 3D structure has been recently determined by X-ray crystallog. and whose agonists have been shown to have neuroprotective activity in neurodegenerative diseases. To identify therapeutic agents against HD, we have implemented a drug repositioning strategy consisting of: (i) Prediction of the ability of the FDA-approved drugs publicly available through the ZINC database to interact with s1R by virtual screening, followed by computational docking and visual examination of the 20 highest scoring drugs; and (ii) Assessment of the ability of the six drugs selected by computational analyses to directly bind purified s1R in vitro by Surface Plasmon Resonance and improve the growth of fibroblasts obtained from HD patients, which is significantly impaired with respect to control cells. All six of the selected drugs proved able to directly bind purified s1R in vitro and improve the growth of HD cells from both or one HD patient. These results support the validity of the drug repositioning procedure implemented herein for the identification of new therapeutic tools against HD. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009) was written by Friedrich, Anita;Olejniczak, Klaus. And the article was included in Regulatory Toxicology and Pharmacology in 2011.Application of 210421-74-2 This article mentions the following:

Carcinogenicity data of medicinal products for human use that have been authorized via the European centralized procedure (CP) between 1995 and 2009 were evaluated. Carcinogenicity data, either from long-term rodent carcinogenicity studies, transgenic mouse studies or repeat-dose toxicity studies were available for 144 active substances contained in 159 medicinal products. Out of these compounds, 94 (65%) were pos. in at least one long-term carcinogenicity study or in repeat-dose toxicity studies. Fifty compounds (35%) showed no evidence of a carcinogenic potential. Out of the 94 compounds with pos. findings in either carcinogenicity or repeat-dose toxicity studies, 33 were pos. in both mice and rats, 40 were pos. in rats only, and 21 were pos. exclusively in mice. Long-term carcinogenicity studies in two rodent species were available for 116 compounds Data from one long-term carcinogenicity study in rats and a transgenic mouse model were available for eight compounds For 13 compounds, carcinogenicity data were generated in only one rodent species. One compound was exclusively tested in a transgenic mouse model. Six compounds were tumorigenic in repeat-dose toxicity studies in rats. The majority of tumor findings observed in rodent carcinogenicity studies were considered not to be relevant for humans, either due to a rodent-specific mechanism of carcinogenicity, a high safety margin between exposures at the NOAEL (No Observed Adverse Effect Level) in rodents and recommended therapeutic doses in humans, or based on historical control data, a small effect size and lack of dose-response relationship and tumors typically observed in rodent strains used, or were considered not to be relevant for humans based on literature and clin. data or likely differences in metabolism/local concentrations between rodents and humans. Due to the high number of rodent tumor findings with unlikely relevance for humans, the value of the currently used testing strategy for carcinogenicity appears questionable. A revision of the carcinogenicity testing paradigm is warranted. In the experiment, the researchers used many compounds, for example, Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2Application of 210421-74-2).

Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Application of 210421-74-2

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem